Novacyt to support UNICEF with donation of one million COVID-19 tests

Donation supports testing efforts to help ensure continued access to essential services for children and their families Paris, France and Camberley, UK – 4 May 2021 – Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT; “Novacyt”), an international clinical diagnostics company, will donate one million COVID-19 polymerase chain reaction (PCR) tests to UNICEF to help contain

Visit Page

R&D and UK operational update

Paris, France and Camberley, UK – 23 April 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces an update on the progress of its near-term COVID-19 research and development (R&D) programmes to address rapidly evolving testing demands, particularly as SARS-CoV-2 continues to mutate around the world. Novacyt also provides

Visit Page

Update on Notice of 2020 Full Year Results

Paris, France and Camberley, UK – 22 April 2021 – Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that following the announcement on 9 April 2021, the Company now intends to report its audited financial results for the year ended 31 December 2020 on 29 June 2021. http://novacyt.com/wp-content/uploads/2021/04/Novacyt-Notice-of-Results-22.04.21-ENGLISH.pdf

Visit Page